Inhibitory effect of fluvastatin at doses insufficient to lower serum lipids on the catheter-induced thickening of intima in rabbit femoral artery

European Journal of Pharmacology

Volumn 315, Issue 1, 1996, Pages 37-42

  Bandoh, Tsutomu ^a   Mitani, Hironobu ^a   Niihashi, Mari ^b   Kusumi, Yoshiaki ^b   Ishikawa, Junji ^a   Kimura, Masaaki ^a   Totsuka, Tetsuya ^a   Sakurai, Isamu ^b   Hayashi, Shigehiro ^a  

^a Sandoz Tsukuba Research Institute   (Japan)

^b NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Balloon catheterization; HMG CoA reductase inhibitor; Hyperplasia

Indexed keywords

CHOLESTEROL; FLUINDOSTATIN; PHOSPHOLIPID; PRAVASTATIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INTIMA PROLIFERATION; ARTICLE; BALLOON CATHETER; CELL MIGRATION; CONTROLLED STUDY; FEMORAL ARTERY; LIPID BLOOD LEVEL; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CATHETERIZATION; CHOLESTEROL; ENZYME INHIBITORS; FATTY ACIDS, MONOUNSATURATED; FEMORAL ARTERY; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERPLASIA; INDOLES; LIPIDS; MALE; MEVALONIC ACID; PHOSPHOLIPIDS; PRAVASTATIN; RABBITS; TRIGLYCERIDES; TUNICA INTIMA;

EID: 0030574249     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(96)00573-0     Document Type: Article

References (29)

1. Chamley-Champbell, J.H. and G.R. Champbell, 1981, What controls smooth muscle phenotype?, Atherosclerosis 40, 347.
2. Chamley-Champbell, J.H., G.R. Champbell and R. Ross, 1981, Phenotype-dependent response of cultured aortic smooth muscle to serum mitogens, J. Cell Biol. 89, 379.
3. Corsini, A., M. Mazzotti, M. Raiteri, M.R. Soma, G. Gabbiani, R. Fumagalli and R. Paoletti, 1993, Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase, Atherosclerosis 101, 117.
4. Doyle, J.W. and A.A. Kandutsch, 1988, Requirement for mevalonate in cycling cells: quantitative and temporal aspects, J. Cell Physiol. 137, 133.
5. Fairbanks, K.P., L.D. Witte and D.S. Goodman, 1984, Relationship between mevalonate and mitogenesis in human fibroblasts stimulated with platelet-derived growth factor, J. Biol. Chem. 259, 1546.
6. Frick, M.H., O. Elo, K. Haapa, O.P. Heinonen, P. Heinsalmi, P. Helo, J.K. Huttunen, P. Kaitaniemi, P. Koskinen, V. Manninen, H. Maenpaa, M. Malkonen, M. Manttari, S. Norola, A. Pasternack, J. Pikkarainen, M. Romo, T. Sjoblom and E.A. Nikkila, 1987, Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia, N. Engl. J. Med. 317, 1237.
7. Goldstein, J.L. and M.S. Brown, 1990, Regulation of the mevalonate pathway, Nature 343, 425.
8. Habenicht, A.J.R., J.A. Glomset and R. Ross, 1980, Relation of cholesterol and mevalonic acid to the cell cycle in smooth muscle and Swiss 3T3 cells stimulated to divide by platelet-derived growth factor, J. Biol. Chem. 255, 5134.
9. Hayashi, K., J. Kurokawa, S. Nomura, Y. Kuga, Y. Ohkura and G Kajiyama, 1993, Effect of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on the induction of low-density lipoprotein receptor in HepG2 cells, Biochim. Biophys. Acta 1167, 223.
10. Hjermann, I., K.V. Byre, I. Holme and P. Leren, 1981, Effect of diet and smoking intervention on the incidence of coronary heart disease, Lancet ii, 1303.
11. Indolfi, C., E.V. Avvedimento, A. Rapacciuolo, E.D. Lorenzo, G. Esposito, E. Stabile, A. Feliciello, E. Mele, P. Giuliano, G. Condorelli and M. Chiariello, 1995, Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo, Nature Med. 1, 541.
12. Lipid Research Clinics Program, 1984, The lipid research clinics coronary primary prevention trial results, J. Am. Med. Ass. 251, 351.
13. Maltese, W.A., 1990, Posttranslational modification of proteins by isoprenoids in mammalian cells, FASEB J. 4, 3319.
14. Maltese, W.A., R. Defendini, R.A. Green, K.M. Sheridan and D.K. Donley, 1985, Suppression of murine neuroblastoma growth in vivo by mevilonin, a competitive inhibitor of 3-hydroxy-3-methylglutarylcoenzyme A reductase, J. Clin. Invest. 76, 1748.
15. Masuda, N., I. Akasaka, J. Suzuki, A. Fujino, M. Ohtawa, N. Nakaya, Y. Goto, N. Takahashi, H. Sekino, T. Amamoto, A. Urae, A. Maeda and S. Irie, 1995, Phase I study of fluvastatin, a new synthetic HMG-CoA reductase inhibitor, Rinsyoiyaku 11, 65.
16. Oliver, M.F., J.A. Heady, J.N. Morris and J. Cooper, 1984, Who cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up, Lancet ii, 600.
17. Parker, R.A., R.W. Clark, S.-Y. Sit, T.L. Lanier, R.A. Grosso and J.J.K. Weight, 1990, Selective inhibition of cholesterol synthesis in liver versus extrahepatic tissues by HMG-CoA reductase inhibitors, J. Lipid Res. 31, 1271.
18. Paterniti, Jr., J.R., 1992, New drugs for inhibiting cholesterol synthesis: experimental studies with fluvastatin, Can. J. Cardiol. 8, 21A.
19. Prous, J. and J. Castaner, 1991, Fluvastatin sodium, Drugs Future 16, 804
20. Quesney-Huneeus, V., H.A. Galick, M.D. Siperstein, S.K. Erickson, T.A. Spencer and J.A. Nelson, 1983, The dual role of mevalonate in the cell cycle, J. Biol. Chem. 258, 378.
21. Quesney-Huneeus, V., M.H. Wiley and M.D. Siperstein, 1979, Essential role for mevalonate synthesis in DNA replication, Proc. Natl. Acad. Sci. USA 76, 5056.
22. Rogler, G., K. J. Lackner and G. Schmitz, 1995, Mevalonate is essential for growth of porcine and human vascular smooth muscle cells in vitro, Basic Res. Cardiol. 90, 443.
23. Scott, W.A., 1989, Hydrophilicity and the differential pharmacology of pravastatin, in: Lipid Management: Pravastatin and the Differential Pharmacology of HMG-CoA Reductase Inhibitors, ed. C. Wood London Round Table Ser. 16 (R. Soc. Med. Serv.), p. 17.
24. Shaw, M.K., R.S. Newton, D.R. Sliskovic, B.D. Roth, E. Ferguson and B.R. Krause, 1990, Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase, Biochim. Biophys. Res. Commun. 170, 726.
25. Shiomi, M., M. Shiraishi, T. Yata and T. Ito, 1994, Effect of fluvastatin sodium on secretion of very low density lipoprotein and serum cholesterol levels. In vivo study using low density lipoprotein receptor deficient Watanabe heritable hyperlipidemic rabbits, Arzncim.-Forsch. 44, 1154.
26. Soma, M.R., E. Donetti, C. Parolini, G. Mazzini, C. Ferrai, R. Fumagalli and R. Paoletti, 1993, HMG-CoA reductase inhibitors: in vivo effects on carotid intimal thickening in normocholesterolemic rabbits, Arterioscler. Thromb. 13, 571.
27. Stamler, J., D. Wentworth and J.D. Neaton, 1986, Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? J. Am. Med. Ass. 256, 2823.
28. Taylor, P.W., 1993, Recent developments in hypolipidemic investigational drugs, Curr. Opin. Invest. Drugs 2, 505.
29. Tsujita, Y., M. Kuroda, Y. Shimada, K. Tanzawa, M. Aral, I. Kaneko, M. Tnaka, H. Masuda, C. Tarumi, Y. Watanabe and S. Fujii, 1986, CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species, Biochim. Biophys. Acta 877, 50.